Robert Glynn, PhD, ScD

Division of Pharmacoepidemiology and Pharmacoeconomics, Dept of Medicine, Brigham and Women's Hospital, Harvard Medical School

Poster(s):

• (043) Utilization of newly approved targeted immunomodulating treatments for atopic dermatitis
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (092) Comparing Healthcare Utilization and Cost in Empagliflozin vs GLP-1RA Initiators with Type 2 Diabetes without Established Cardiovascular Disease
  Wednesday, August 28, 2024

  8:00 AM – 1:30 PM CEST

• (205) Co-Administration of Oxycodone and CYP3A4-Inhibiting Calcium Channel Blockers and Opioid Overdose: Real-World Evidence from Population-based Claims Data in the United States, 2000-2020.
  Wednesday, August 28, 2024

  8:00 AM – 1:30 PM CEST